drugset / Trial / NCT06260722

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

NCT06260722

Phase 3 Active not recruiting 1250 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.

Timeline

Start
2024-02-21
Primary completion
2026-08
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Retatrutide Protein / enzyme biologic Subcutaneous
Comparator Semaglutide Peptide Subcutaneous